The funding round was led by Triple Point, Cass Entrepreneurship Fund, and Alliance Fund Managers to support international expansion and platform growth.
"Every young person deserves equal access to opportunities with amazing employers and universities and the guidance to make informed decisions. Too often this is dependent on the school you attend or the professional network you can tap into. Springpod democratises access to top organisations and provides students with the toolset to explore, prepare for and secure their dream next step, from age 13-24."
The oversubscribed round was led by Techstart Ventures with participation from Clarendon Fund Managers and angels.
"We intend to use the funds to build partnerships and upscale our marketing efforts within Ireland. We have recently partnered with Visa to expand into the Irish market and this investment will allow us to accelerate our rollout of the app to local businesses."
The seed round was led by SuperSeed with backing from private investors to support marketing and technology expansion.
"Our ambition is to empower brands to build a truly impactful localisation strategy from the start, not as an afterthought. We want to encourage greater appreciation and knowledge of the cultural differences and similarities across the world, so brands can better connect with local audiences and compete with local incumbents."
NPIF - Maven Equity Finance led the funding round, with additional backing from the Future Fund, to support the company as it expands its customer reach.
"At the heart of the eviid platform sits our unique patented evidential technology as well as a robust system for handling video in enterprise contexts. It’s incredibly scalable, with applications in numerous sectors beyond the ones we are serving today. The pandemic has really put video on the map and businesses around the world have realised how much can be done remotely. We have a long-term solution for this – a secure and proven system for integrating video and images into business workflows."
The University of Edinburgh spin-out has secured backing to fund its first human trials.
"The BioCollector is a disruptive technology which will be transformational for liquid biopsy testing. We are confident that this platform technology can make a significant impact in this important area and, ultimately, enable cancers to be detected more quickly and accurately, enabling patients to receive precision cancer treatment as early as possible."
